ArticleVox sanguinis2021
Evaluation of SARS-CoV-2 antibody titers and potency for convalescent plasma donation: a brief commentary.
Article in Vox sanguinis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Intranasal administration of convalescent plasma protects against SARS-CoV-2 infection in hamsters.EBioMedicine · 2023Pooled it
- Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19.The Journal of clinical investigation · 2021Trial
- COVID-19 convalescent plasma: current status, lessons from the past and future perspectives.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2022Article
- Qualifying coronavirus disease 2019 convalescent plasma donors in Israel.Vox sanguinis · 2022Article
- Persistence of SARS-CoV-2 total immunoglobulins in a series of convalescent plasma and blood donors.PloS one · 2022Article
- International Forum on the Collection and Use of COVID-19 Convalescent Plasma: Responses.Vox sanguinis · 2021Article
- A novel competition ELISA for the rapid quantification of SARS-CoV-2 neutralizing antibodies in convalescent plasma.Transfusion · 2021Article
- Convalescent plasma to treat COVID-19: Following the Argentinian lead.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2021Review
- Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2021Article
- The Three Pillars of COVID-19 Convalescent Plasma Therapy.Life (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.